Zobrazit v EDS

Comparative study of chikungunya Virus-Like Particles and Pseudotyped-Particles used for serological detection of specific immunoglobulin M

Uloženo v:
Podrobná bibliografie
Název: Comparative study of chikungunya Virus-Like Particles and Pseudotyped-Particles used for serological detection of specific immunoglobulin M
Autoři: Christophe Steinbrugger, Dimitri Lavillette, Pascal Dalbon, Bruno Coutard, Nicolas Papageorgiou, Frederic Bedin, Isabelle Leparc-Goffart, Jérôme Martinez, Gerald Theillet
Přispěvatelé: BUISINE, Soline, BIOMERIEUX Lyon, France, Unité des Virus Emergents (UVE), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Systèmes Macromoléculaires et Physiopathologie Humaine (SMPH), BIOMERIEUX Lyon, France -Centre National de la Recherche Scientifique (CNRS), CAS Key Laboratory of Molecular Virology and Immunology Shangai, Institut Pasteur de Shanghai, Académie des Sciences de Chine - Chinese Academy of Sciences (IPS-CAS), Pasteur Network (Réseau International des Instituts Pasteur)-Pasteur Network (Réseau International des Instituts Pasteur), Architecture et fonction des macromolécules biologiques (AFMB), Institut National de la Recherche Agronomique (INRA)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Institut de Recherche Biomédicale des Armées Antenne Marseille (IRBA), Centre National de Référence des Arbovirus Marseille, Institut de Recherche Biomédicale des Armées Antenne Marseille (IRBA)-Unité d'Arbovirologie Marseille, Hôpital d'Instruction des Armées Laveran, Service de Santé des Armées-Service de Santé des Armées-Hôpital d'Instruction des Armées Laveran, Service de Santé des Armées-Service de Santé des Armées, This study was funded by BioMerieux SA, France and Agence Nationale de la Recherche et de la Technologie, France (G. Theillet's grant CIFRE ID 2015/0514).
Zdroj: Virology. 529:195-204
Informace o vydavateli: Elsevier BV, 2019.
Rok vydání: 2019
Témata: 0301 basic medicine, [SDV.BIO]Life Sciences [q-bio]/Biotechnology, Pseudotyped virus, Viral/immunology, Enzyme-Linked Immunosorbent Assay, MESH: Chikungunya virus/physiology, Field-flow fractionation, Antibodies, Viral, Sensitivity and Specificity, 03 medical and health sciences, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Antibody Specificity, Humans, MESH: Serologic Tests/methods, Serologic Tests, MESH: Antibody Specificity, Arbovirus, [SDV.MP.VIR] Life Sciences [q-bio]/Microbiology and Parasitology/Virology, [SDV.MHEP.ME] Life Sciences [q-bio]/Human health and pathology/Emerging diseases, [SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases, 0303 health sciences, MESH: Humans, MESH: Antibodies, MESH: Chikungunya Fever/diagnosis, MESH: Enzyme-Linked Immunosorbent Assay, Virus-like particles, MESH: Sensitivity and Specificity, [SDV.BIO] Life Sciences [q-bio]/Biotechnology, 3. Good health, MESH: Immunoglobulin M/immunology, Immunoglobulin M, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, [SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Chikungunya Fever, Chikungunya, Chikungunya virus
Popis: The incidence of chikungunya virus (CHIKV) infection has increased dramatically in recent decades. Effective diagnostic methods must be available to optimize patient management. IgM-capture Enzyme-Linked Immunosorbent Assay (MAC-ELISA) is routinely used for the detection of specific CHIKV IgM. This method requires inactivated CHIKV viral lysate (VL). The use of viral bioparticles such as Virus-Like Particles (VLPs) and Pseudotyped-Particles (PPs) could represent an alternative to VL. Bioparticles performances were established by MAC-ELISA; physico-chemical characterizations were performed by field-flow fractionation (HF5) and confirmed by electron microscopy. Non-purified PPs give a detection signal higher than for VL. Results suggested that the signal difference observed in MAC-ELISA was probably due to the intrinsic antigenic properties of particles. The use of CHIKV bioparticles such as VLPs and PPs represents an attractive alternative to VL. Compared to VL and VLPs, non-purified PPs have proven to be more powerful antigens for specific IgM capture.
Druh dokumentu: Article
Popis souboru: application/pdf
Jazyk: English
ISSN: 0042-6822
DOI: 10.1016/j.virol.2019.01.027
Přístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/30721816
https://www.ncbi.nlm.nih.gov/pubmed/30721816
https://www.sciencedirect.com/science/article/pii/S0042682219300303
https://pubmed.ncbi.nlm.nih.gov/30721816/
https://www.sciencedirect.com/science/article/abs/pii/S0042682219300303
https://inserm.hal.science/inserm-02374934v1/document
https://doi.org/10.1016/j.virol.2019.01.027
https://inserm.hal.science/inserm-02374934v1
Rights: Elsevier Non-Commercial
Přístupové číslo: edsair.doi.dedup.....1c19d8a6639105541ff7e130655f6f98
Databáze: OpenAIRE
Popis
Abstrakt:The incidence of chikungunya virus (CHIKV) infection has increased dramatically in recent decades. Effective diagnostic methods must be available to optimize patient management. IgM-capture Enzyme-Linked Immunosorbent Assay (MAC-ELISA) is routinely used for the detection of specific CHIKV IgM. This method requires inactivated CHIKV viral lysate (VL). The use of viral bioparticles such as Virus-Like Particles (VLPs) and Pseudotyped-Particles (PPs) could represent an alternative to VL. Bioparticles performances were established by MAC-ELISA; physico-chemical characterizations were performed by field-flow fractionation (HF5) and confirmed by electron microscopy. Non-purified PPs give a detection signal higher than for VL. Results suggested that the signal difference observed in MAC-ELISA was probably due to the intrinsic antigenic properties of particles. The use of CHIKV bioparticles such as VLPs and PPs represents an attractive alternative to VL. Compared to VL and VLPs, non-purified PPs have proven to be more powerful antigens for specific IgM capture.
ISSN:00426822
DOI:10.1016/j.virol.2019.01.027